Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Sales | 824,566 | 790,990 | 743,300 | 682,584 | 707,059 |
| Cost of Goods | 516,288 | 491,022 | 454,026 | 450,346 | 454,998 |
| Gross Profit | 308,278 | 299,968 | 289,274 | 232,238 | 252,061 |
| Operating Expenses | 184,863 | 171,063 | 156,547 | 155,816 | 158,778 |
| Operating Income | 123,703 | 128,927 | 132,753 | 76,768 | 94,281 |
| Interest Expense | 29,719 | 33,147 | 18,867 | 19,352 | 15,067 |
| Other Income | -27,682 | 76,647 | 21,390 | 26,536 | -23,755 |
| Pre-tax Income | 66,302 | 172,427 | 135,276 | 83,952 | 55,459 |
| Income Tax | 2,367 | 28,237 | 32,665 | 16,284 | 4,622 |
| Net Income Continuous | 63,935 | 144,190 | 102,611 | 67,668 | 50,837 |
| Minority Interests | 2,405 | 999 | -298 | 233 | 68 |
| Net Income | $61,530 | $143,191 | $102,909 | $67,435 | $50,769 |
| EPS Basic Total Ops | 1.23 | 2.89 | 2.07 | 1.36 | 1.03 |
| EPS Basic Continuous Ops | 1.28 | 2.91 | 2.06 | 1.37 | 1.03 |
| EPS Diluted Total Ops | 1.20 | 2.81 | 2.03 | 1.34 | 1.02 |
| EPS Diluted Continuous Ops | 1.25 | 2.83 | 2.02 | 1.35 | 1.02 |
| EBITDA(a) | $185,211 | $189,803 | $192,333 | $133,976 | $151,541 |